Infant nutrition company Biotime is just the latest of such companies within China to modify its business practices following the announcement of an antirust investigation into the sector by Chinese authorities. The nation’s National Reform and Development Commission launched a probe into various makers of infant formula for suspicion of price-fixing. Biostime announced Tuesday plans to revise contracts with its distributors, according to reports. The case is particular, however, as reports say the price-fixing probe focuses on foreign companies in the market; Biostime is a domestic company. The company’s wholly-owned Chinese subsidiary is currently under investigation by the NDRC.
Featured News
New Mexico Jury Orders Meta to Pay $375 Million in Consumer Protection Case
Mar 24, 2026 by
CPI
CVS Health Nears FTC Settlement Over Insulin Pricing Practices
Mar 24, 2026 by
CPI
South Korean Food Giant CJ Cheiljedang Apologizes Again in Sugar Collusion Case
Mar 24, 2026 by
CPI
EU Competition Chief to Press Big Tech on AI Power During US Visit
Mar 24, 2026 by
CPI
Colorado Eying Possible Do-Over of Landmark AI Law
Mar 24, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Data-Driven Competition
Mar 19, 2026 by
CPI
Data-Driven Competition: Implications For Enforcement and Merger Control
Mar 19, 2026 by
Alexandre de Corniere & Greg Taylor
From Tipping to Trustees: Why Data-Driven Markets Require Institutional Design, Not Optimization
Mar 19, 2026 by
Jens Prüfer & Paul de Bijl
Data Barriers to Entry: What We’ve Learned About Spotting Them and What We Still Don’t Know About Solutions
Mar 19, 2026 by
Bruno Carballa-Smichowski
When the Perfect Is the Enemy of the Good: Price Discrimination, Affordability, Precarity and Market Dynamism
Mar 19, 2026 by
Dan Ciuriak